// App-Quantinova.ai

: Incidence and Risk of Major Bleeding in Patients with End‐stage Renal Disease on Hemodialysis with and without Antithrombotic Therapy: Prospective Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in HemoDIalysis Patients (VIVALDI)

Researchers

Presenter

  • O. Koenigsbruegge

Principal Investigators

  • H. Meisel

  • S. Schmaldienst

  • M. Auinger

  • M. Lorenz

  • R. Klauser-Braun

  • J. Kletzmayr

  • I. Pabinger

  • M. Semann

  • C. Ay

Medical Centers

  • Medical University, Department of Internal Medicine III, Vienna, Austria

  • Kaiser‐Franz‐Josef‐Spital, Department of Medicine I, Vienna, Austria

  • Krankenhaus Hietzing, Department of Medicine III, Vienna, Austria

  • Vienna Dialysis Center, Vienna, Austria

  • Donauspital, Department of Medicine III, Vienna, Austria

  • Wilhelminenspital, Department of Medicine VI, Vienna, Austria

Locations

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Pulmonary/Respiratory Diseases

  • Central Nervous System (CNS)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • End stage renal disease

  • Arrhythmia

  • Venous thrombosis

  • Renal disease

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved